Overview

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of subcutaneous MOA-728 versus placebo in subjects with chronic non-malignant pain who have Opioid-Induced Constipation (OIC).

Phase:

Phase 3

Details

Lead Sponsor:

Bausch Health Americas, Inc.
Valeant Pharmaceuticals International, Inc.

Collaborator:

Progenics Pharmaceuticals, Inc.

Treatments:

Analgesics, Opioid
Bromides
Methylnaltrexone
Naltrexone